Melanoma patients with previous targeted therapy (with BRAF and MEK inhibitors) experience a significantly longer time lapse between ICI initiation and VLL onset compared to non-pretreated patients (12.5 vs. 6.2 months) [34,35]. Here, MAP2K7 is linked to melanoma.